Form 8-K
8-K — LEMAITRE VASCULAR INC
Accession: 0001193125-26-447467
Filed: 2026-11-04
Period: 2026-11-04
CIK: 0001158895
SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)
Item: Results of Operations and Financial Condition
Item: Financial Statements and Exhibits
Documents
8-K — d171050d8k.htm (Primary)
EX-99.1 (d171050dex991.htm)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: d171050d8k.htm · Sequence: 1
8-K
LEMAITRE VASCULAR INC false 0001158895 0001158895 2026-11-04 2026-11-04
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 4, 2026
LeMaitre Vascular, Inc.
(Exact name of registrant as specified in its charter)
Commission File Number: 001-33092
Delaware
04-2825458
(State or other jurisdiction
of incorporation)
(IRS Employer
Identification No.)
63 Second Avenue
Burlington, MA 01803
(Address of principal executive offices, including zip code)
781-221-2266
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each class
Trading
symbol
Name of exchange
on which registered
Common stock, $0.01 par value per share
LMAT
The Nasdaq Global Market
Indicate by checkmark whether the company is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On November 4, 2026, LeMaitre Vascular, Inc. (the “Company”) issued a press release regarding its preliminary financial and operational results for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Report.
The information in this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Disclaimer on Forward-Looking Statements
This current report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements regarding the Company’s business that are not historical facts may be “forward-looking statements” that involve risks and uncertainties. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results predicted. These risks and uncertainties include risks and uncertainties included under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as updated by its subsequent filings with the SEC, all of which are available on the Company’s investor relations website at http://www.lemaitre.com and on the SEC’s website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
Item 9.01. Financial Statements and Exhibits.
The following exhibits are furnished or filed as part of this Report, as applicable:
(d) Exhibits.
Exhibit No.
Description
99.1
Press release issued by LeMaitre Vascular, Inc. on November 4, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signature(s)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LeMaitre Vascular, Inc.
Date: November 4, 2026
By:
Dorian P. LeBlanc
/s/ DORIAN P. LEBLANC
Chief Financial Officer
Exhibit Index
Exhibit No.
Description
99.1
Press release issued by LeMaitre Vascular, Inc. on November 4, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
EX-99.1
EX-99.1
Filename: d171050dex991.htm · Sequence: 2
EX-99.1
Exhibit 99.1
LeMaitre Q3 2026 Financial Results
BURLINGTON, MA, November 4, 2026 – LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today
reported Q3 2026 results, announced a quarterly dividend of $0.25/share, and provided guidance.
Q3 2026:
•
Sales $68.0mm, +11% (+12% organic) vs. Q3 2025
•
Gross margin 71.7% (-360bps, +90 bps vs. adjusted)
•
Op. expenses $31.0mm (+21%, +18% vs. adjusted)
•
Op. income $17.7mm (-13%, +5% vs. adjusted)
•
Op. margin 26%
•
EPS $0.65 (-14%, +5% vs. adjusted)
•
Cash up $13.5mm sequentially to $390mm at 9/30/2026
Grafts (+20%) and shunts (+14%) drove Q3 growth. Artegraft sales increased 18%. EMEA sales increased by 18%, Americas 9%, and APAC 5%. 12% organic growth was
comprised of 7% price and 5% units.
Gross margin of 71.7% was up 90 bps (vs. adjusted) due to higher ASPs and operational efficiencies. Operating
expenses increased 18% (vs. adjusted) due to Q3 2025 belt-tightening. Headcount of 678 increased 7% versus 9/30/2025 while rep count increased 13% to 171.
In October, the company acquired certain vascular assets from B. Braun for $19.2mm. These polyester and silver-coated grafts, valve cutters and vein strippers
recorded sales of $9.4mm in 2025, all outside of North America. Sales will transition into LeMaitre’s channel over the next 18-24 months as B. Braun’s customer contracts conclude or transfer to
LeMaitre. During this transition, LeMaitre will receive a portion of the profits on B. Braun-originated sales.
Chairman/CEO George LeMaitre said,
“We expect 2026 to be another year of healthy sales (+11%) and EPS growth (+18%). Biologics continue to drive sales due to Artegraft’s international launch and the continued growth of RestoreFlow Allografts. The acquired B. Braun
products will strengthen our core vascular portfolio while leveraging our expanding 31-country sales force.”
Business Outlook
Q4 2026 Guidance
Full Year 2026 Guidance
Sales
$69.9mm - $71.9mm
(Mid $70.9mm, +10%, +11% org.)
$274.8mm - $276.8mm
(Mid $275.8mm, +11%, +11% org.)
Gross Margin
72.1%
72.1%
Op. Income
$18.8mm - $20.2mm
(Mid $19.5mm, +4%)
$74.6mm - $76.1mm
(Mid $75.4mm, +11%, +17% adj.)
Op. Margin (Mid)
27%
27%
EPS
$0.70 - $0.75
(Mid $0.73, +7%)
$2.77 - $2.82
(Mid $2.80, +11%, +18% adj.)
*
The top- and bottom-line impacts of the newly acquired B. Braun
products are reflected in this Business Outlook. LeMaitre anticipates recording ~$150,000 of Q4 2026 B. Braun product sales and break-even operating income impact.
**
2025 results include a Q3 non-recurring benefit from the Employee
Retention Tax Credit. Non-GAAP adjusted figures exclude this benefit. A reconciliation of GAAP to non-GAAP measures is included.
Quarterly Dividend
On October 27, 2026, the
Company’s Board of Directors approved a quarterly dividend of $0.25/share of common stock. The dividend will be paid on December 3, 2026, to stockholders of record on November 19, 2026.
Share Repurchase Program
On February 19, 2026, the
Company’s Board of Directors authorized the repurchase of up to $100.0mm of the Company’s common stock. The repurchase program may be suspended or discontinued at any time and will conclude on February 18, 2027, unless extended by
the Board.
Conference Call Reminder
Management will conduct a conference call at 5:00pm ET today. The conference call will be broadcast live over the Internet. Individuals interested in
listening to the webcast can log on to the Company’s website at www.lemaitre.com/investor. Access to the live call is available by registering online here. All registrants will receive
dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. For individuals unable to
join the live conference call, a replay will be available on the Company’s website.
A reconciliation of GAAP to
non-GAAP results is included in the tables attached to this release.
About LeMaitre
LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than
200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.
LeMaitre is a registered trademark of LeMaitre Vascular, Inc. This press release may include other trademarks and trade names of the Company.
For more information about the Company, please visit www.lemaitre.com.
Use of Non-GAAP Financial Measures
LeMaitre management believes that in order to better understand the Company’s short- and long-term financial trends, investors may wish to consider
certain non-GAAP financial measures as a supplement to financial performance measures prepared in accordance with GAAP. Non-GAAP financial measures are not based on a
comprehensive set of accounting rules or principles and do not have standardized meanings. These non-GAAP measures result from facts and circumstances that may vary in frequency and/or impact on continuing
operations. Non-GAAP measures should be considered in addition to, and not as a substitute for, GAAP financial performance measures. In addition to the description provided below, reconciliation of GAAP to non-GAAP results is provided in the financial statement tables included in this press release.
In this press release,
the Company has reported non-GAAP sales growth percentages after adjusting for the impact of foreign currency exchange, business development transactions, and/or other events. The Company refers to the
calculation of non-GAAP sales growth percentages as “organic” or “adjusted.” The Company analyzes non-GAAP sales on a constant currency basis,
net of acquisitions and other non-recurring events. Because changes in foreign currency exchange rates have a non-operating impact on net sales, and acquisitions,
divestitures, product discontinuations, factory closures, and other strategic transactions are episodic in nature and are highly variable to the reported sales results, the Company believes that evaluating growth in sales on a constant currency
basis net of such transactions provides an additional and meaningful assessment of sales to management. Additionally, the Company has provided percentages for Q3 2026 operating income, gross margin, operating expense and EPS, as well as operating
income and EPS guidance, adjusted to exclude the effects of the employee retention tax credit received in 2025. Management believes that viewing growth in these measures excluding those effects provides an alternative and meaningful view of the
Company’s profitability.
Investors are encouraged to review the reconciliation of these non-GAAP financial
measures to their most directly comparable GAAP financial measures set forth in the tables captioned “Reconciliation of GAAP to Non-GAAP Financial Measures” below.
Forward-Looking Statements
The Company’s current
financial results, as discussed in this release, are preliminary and unaudited, and subject to adjustment. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Statements in this press release regarding the Company’s business that are not historical facts may be “forward-looking statements” that involve risks and uncertainties. Forward-looking statements are based on management’s
current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results expected, including, but not limited to, our ability to maintain historic levels of profit growth; our ability to
increase the selling prices of our products; the status of our regulatory approvals, compliance with regulatory requirements, and the potential for adverse regulatory findings or enforcement actions arising from inspections, audits, or other
regulatory reviews, affecting our ability to market and sell our products domestically and internationally; our ability to source, acquire, and integrate acquisitions; our dependence on sole- or limited-source suppliers; competition from other
medical device companies and alternative medical technologies; our ability to engage sales call points other than vascular surgeons; disruptions to our information technology systems or breaches of our information security systems; our
implementation of our new enterprise resource planning system; our ability to procure, process, and preserve human tissue and comply with relevant regulatory requirements; the impact of a disruption in our manufacturing facilities; our ability to
navigate the risks inherent in operating internationally; our ability to transition to direct sales models in certain international territories; the occurrence of
litigation relating to product liability, employment matters, intellectual property, contract disputes, and other matters; the occurrence of product defects or recalls; our ability to service and
repurchase our debt; the dilutive effect of a conversion of our debt; our ability to navigate executive officer transitions and retain key personnel; our ability to protect our intellectual property; volatility in the price of our common stock; and
other risks and uncertainties included under the heading “Risk Factors” in our most recent Annual Report on Form 10-K, as updated by our subsequent filings with the SEC, which are all
available on the Company’s investor relations website at http://www.lemaitre.com and on the SEC’s website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only
as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated
events.
Contact:
ir@lemaitre.com
LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)
CONDENSED CONSOLIDATED BALANCE SHEETS
(amounts in
thousands)
September 30, 2026
December 31, 2025
(unaudited)
Assets
Current assets:
Cash and cash equivalents
$
27,493
$
28,244
Short-term marketable securities
362,228
330,876
Accounts receivable, net
35,876
33,610
Inventory and other deferred costs
71,272
70,422
Prepaid expenses and other current assets
8,642
5,080
Total current assets
505,511
468,232
Property and equipment, net
30,465
26,997
Right-of-use
leased assets
18,503
15,762
Goodwill
65,945
65,945
Other intangibles, net
29,295
33,089
Deferred tax assets
746
759
Other assets
5,567
4,906
Total assets
$
656,032
$
615,690
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable
$
4,159
$
3,646
Accrued expenses
26,686
29,411
Acquisition-related obligations
583
322
Lease liabilities - short-term
3,192
2,944
Total current liabilities
34,620
36,323
Convertible senior notes, net
169,317
168,645
Lease liabilities - long-term
16,342
14,003
Deferred tax liabilities
2,167
1,735
Other long-term liabilities
1,455
1,468
Total liabilities
223,901
222,174
Stockholders’ equity
Common stock
245
244
Additional paid-in capital
238,938
228,407
Retained earnings
215,324
184,715
Accumulated other comprehensive loss
(4,460
)
(2,411
)
Treasury stock
(17,916
)
(17,439
)
Total stockholders’ equity
432,131
393,516
Total liabilities and stockholders’ equity
$
656,032
$
615,690
LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(amounts
in thousands, except per share amounts)
(unaudited)
For the three months ended
For the nine months ended
September 30, 2026
September 30, 2025
September 30, 2026
September 30, 2025
Net sales
$
67,970
$
61,046
$
204,903
$
185,149
Cost of sales
19,265
15,091
57,038
52,800
Gross profit
48,705
45,955
147,865
132,349
Operating expenses:
Sales and marketing
14,506
11,923
43,429
41,030
General and administrative
12,083
10,750
35,239
31,633
Research and development
4,421
2,970
13,328
10,606
Total operating expenses
31,010
25,643
91,996
83,269
Income from operations
17,695
20,312
55,869
49,080
Other income (expense):
Investment income
3,365
3,864
10,075
9,747
Interest expense
(1,304
)
(1,297
)
(3,906
)
(3,886
)
Other income (loss), net
(82
)
(306
)
(503
)
(57
)
Income before income taxes
19,674
22,573
61,535
54,884
Provision for income taxes
4,650
5,211
13,782
12,732
Net income
$
15,024
$
17,362
$
47,753
$
42,152
Earnings per share of common stock
Basic
$
0.66
$
0.77
$
2.09
$
1.86
Diluted
$
0.65
$
0.75
$
2.07
$
1.84
Weighted - average shares outstanding:
Basic
22,871
22,660
22,844
22,615
Diluted
23,071
24,392
23,064
22,915
Cash dividends declared per common share
$
0.25
$
0.20
$
0.75
$
0.60
LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(amounts
in thousands)
(unaudited)
For the nine months ended
September 30, 2026
September 30, 2025
Operating activities
Net income
$
47,753
$
42,152
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation and amortization
8,170
7,813
Stock-based compensation
6,056
5,730
Amortization of issuance costs on convertible notes
672
653
Non-cash investment income
(253
)
—
Provision for inventory write-downs
2,548
1,893
Provision for credit losses
675
455
Foreign currency transaction effect on income
316
(79
)
Changes in operating assets and liabilities:
Accounts receivables
(3,347
)
(1,403
)
Inventory and other deferred costs
(3,584
)
(6,805
)
Prepaid expenses and other assets
(4,244
)
1,639
Accounts payable and other liabilities
(636
)
5,327
Accrued interest
(1,078
)
719
Net cash provided by operating activities
53,048
58,094
Investing activities
Purchases of short-term marketable securities
(390,987
)
(43,015
)
Purchases of property and equipment
(7,429
)
(5,006
)
Payments related to acquisitions, net of cash acquired
(194
)
(95
)
Proceeds from short-term marketable securities
358,201
—
Net cash used in investing activities
(40,409
)
(48,116
)
Financing activities
Proceeds from stock option exercises
4,473
4,657
Deferred payments for acquisitions
(95
)
(1,433
)
Payment of withholding taxes in connection with net settlement of equity awards
(477
)
(605
)
Common stock cash dividend paid
(17,144
)
(13,572
)
Net cash used in financing activities
(13,243
)
(10,953
)
Effect of exchange rate changes on cash and cash equivalents
(147
)
859
Net (decrease) increase in cash and cash equivalents
(751
)
(116
)
Cash and cash equivalents at beginning of period
28,244
25,610
Cash and cash equivalents at end of period
$
27,493
$
25,494
LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)
SELECTED NET SALES INFORMATION
(amounts in thousands)
(unaudited)
For the three months ended
For the nine months ended
September 30, 2026
September 30, 2025
September 30, 2026
September 30, 2025
$
%
$
%
$
%
$
%
Net Sales by Geography
Americas
$
42,713
63
%
$
39,218
64
%
$
127,763
62
%
$
119,496
64
%
Europe, Middle East and Africa
20,830
31
%
17,631
29
%
63,254
31
%
53,431
29
%
Asia Pacific
4,427
6
%
4,197
7
%
13,886
7
%
12,222
7
%
Total Net Sales
$
67,970
100
%
$
61,046
100
%
$
204,903
100
%
$
185,149
100
%
LEMAITRE VASCULAR, INC (NASDAQ: LMAT)
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(amounts in thousands)
(unaudited)
For the three months ended
For the nine months ended
September 30, 2026
September 30, 2025
September 30, 2026
September 30, 2025
Reconciliation between GAAP Net Income and Non-GAAP
Adjusted EBITDA
Net income as reported
$
15,024
$
17,362
$
47,753
$
42,152
Employee retention tax credit, net
—
(3,380
)
—
(3,380
)
Interest (income) expense, net
(2,061
)
(2,567
)
(6,169
)
(5,861
)
Amortization and depreciation expense
2,885
2,612
8,170
7,812
Provision for income taxes
4,650
5,211
13,782
12,732
Adjusted EBITDA
$
20,498
$
19,238
$
63,536
$
53,455
Adjusted EBITDA percentage increase
7
%
19
%
LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(amounts in thousands)
(unaudited)
Reconciliation between GAAP and Non-GAAP sales
growth:
For the three months ended September 30, 2026
Net sales as reported
$
67,970
Impact of currency exchange rate fluctuations
439
Adjusted net sales
$
68,409
For the three months ended September 30, 2025
Net sales as reported
$
61,046
Adjusted net sales
$
61,046
Adjusted net sales increase for the three months ended September 30, 2026
$
7,363
12
%
Reconciliation between GAAP and Non-GAAP gross margin
growth:
For the three months ended September 30, 2026
Gross margin as reported
71.7
%
Adjusted gross margin
71.7
%
For the three months ended September 30, 2025
Gross margin as reported
75.3
%
Employee Retention Tax Credit impact
-4.5
%
Adjusted gross margin
70.8
%
Adjusted gross margin increase for the three months ended September 30, 2026
0.9
%
Reconciliation between GAAP and Non-GAAP operating expense
growth:
For the three months ended September 30, 2026
Operating expense as reported
$
31,010
Adjusted operating expense
$
31,010
For the three months ended September 30, 2025
Operating expense as reported
$
25,643
Employee Retention Tax Credit impact
667
Adjusted operating expense
$
26,310
Adjusted operating expense increase for the three months ended September 30, 2026
$
4,700
18
%
Reconciliation between GAAP and Non-GAAP operating income
growth:
For the three months ended September 30, 2026
Operating income as reported
$
17,695
Adjusted operating income
$
17,695
For the three months ended September 30, 2025
Operating income as reported
$
20,312
Employee Retention Tax Credit impact
(3,380
)
Adjusted operating income
$
16,932
Adjusted operating income increase for the three months ended September 30, 2026
$
763
5
%
Reconciliation between GAAP and Non-GAAP earnings per
share growth:
For the three months ended September 30, 2026
Earnings per share as reported
$
0.65
Adjusted earnings per share
$
0.65
For the three months ended September 30, 2025
Earnings per share as reported
$
0.75
Employee Retention Tax Credit impact
(0.13
)
Adjusted earnings per share
$
0.62
Adjusted earnings per share increase for the three months ended September 30, 2026
$
0.03
5
%
LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(amounts in thousands)
(unaudited)
Reconciliation between GAAP and Non-GAAP projected sales
growth:
For the three months ending December 31, 2026
Net sales per guidance (midpoint)
$
70,900
Impact of currency exchange rate fluctuations
507
Adjusted projected net sales
$
71,407
For the three months ended December 31, 2025
Net sales as reported
$
64,453
Adjusted net sales
$
64,453
Adjusted projected net sales increase for the three months ending December 31, 2026
$
6,954
11
%
Reconciliation between GAAP and Non-GAAP projected sales
growth:
For the year ending December 31, 2026
Net sales per guidance (midpoint)
$
275,800
Impact of currency exchange rate fluctuations
(1,433
)
Adjusted projected net sales
$
274,367
For the year ended December 31, 2025
Net sales as reported
$
249,602
Net impact of divestitures excluding currency
(1,839
)
Adjusted net sales
$
247,763
Adjusted projected net sales increase for the year ending December 31, 2026
$
26,604
11
%
Reconciliation between GAAP and Non-GAAP projected
operating income growth:
For the year ending December 31, 2026
Operating income per guidance (midpoint)
$
75,400
Projected operating income
$
75,400
For the year ended December 31, 2025
Operating income as reported
$
67,912
Impact of employee retention credit
(3,380
)
Adjusted operating income
$
64,532
Adjusted projected operating income increase for the year ending December 31, 2026
$
10,868
17
%
Reconciliation between GAAP and Non-GAAP earnings per
share growth:
For the year ending December 31, 2026
Earnings per share per guidance (midpoint)
$
2.80
Projected earnings per share
$
2.80
For the year ended December 31, 2025
Earnings per share as reported
$
2.52
Impact of employee retention credit
(0.14
)
Adjusted earnings per share
$
2.38
Adjusted projected earnings per share increase for the year ending December 31, 2026
$
0.42
18
%
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 7
v3.26.3
Document and Entity Information
Nov. 04, 2026
Cover [Abstract]
Entity Registrant Name
LEMAITRE VASCULAR INC
Amendment Flag
false
Entity Central Index Key
0001158895
Document Type
8-K
Document Period End Date
Nov. 04, 2026
Entity File Number
001-33092
Entity Incorporation State Country Code
DE
Entity Tax Identification Number
04-2825458
Entity Address, Address Line One
63 Second Avenue
Entity Address, City or Town
Burlington
Entity Address, State or Province
MA
Entity Address, Postal Zip Code
01803
City Area Code
781
Local Phone Number
221-2266
Written Communications
false
Soliciting Material
false
Pre Commencement Tender Offer
false
Pre Commencement Issuer Tender Offer
false
Security 12b Title
Common stock, $0.01 par value per share
Trading Symbol
LMAT
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration